SE9800550D0 - A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof - Google Patents

A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof

Info

Publication number
SE9800550D0
SE9800550D0 SE9800550A SE9800550A SE9800550D0 SE 9800550 D0 SE9800550 D0 SE 9800550D0 SE 9800550 A SE9800550 A SE 9800550A SE 9800550 A SE9800550 A SE 9800550A SE 9800550 D0 SE9800550 D0 SE 9800550D0
Authority
SE
Sweden
Prior art keywords
angiotensin
type
receptor agonist
pharmaceutical preparation
dyspepsia
Prior art date
Application number
SE9800550A
Other languages
English (en)
Swedish (sv)
Inventor
Lars Faendriks
Anders Pettersson
Anders Hallberg
Original Assignee
A & Science Invest Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A & Science Invest Ab filed Critical A & Science Invest Ab
Priority to SE9800550A priority Critical patent/SE9800550D0/xx
Publication of SE9800550D0 publication Critical patent/SE9800550D0/xx
Priority to CA002319123A priority patent/CA2319123A1/en
Priority to BR9908188-1A priority patent/BR9908188A/pt
Priority to IDW20001909A priority patent/ID26639A/id
Priority to IL13799099A priority patent/IL137990A0/xx
Priority to PCT/SE1999/000262 priority patent/WO1999043339A1/en
Priority to EEP200000481A priority patent/EE200000481A/xx
Priority to AU27537/99A priority patent/AU755949B2/en
Priority to JP2000533135A priority patent/JP2002504516A/ja
Priority to KR1020007009295A priority patent/KR20010041211A/ko
Priority to CN99803230A priority patent/CN1291104A/zh
Priority to NZ506188A priority patent/NZ506188A/xx
Priority to HU0101411A priority patent/HUP0101411A3/hu
Priority to SK1152-2000A priority patent/SK11522000A3/sk
Priority to EP99908017A priority patent/EP1066048A1/en
Priority to MXPA00008172A priority patent/MXPA00008172A/es
Priority to IS5594A priority patent/IS5594A/is
Priority to NO20004215A priority patent/NO20004215L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE9800550A 1998-02-24 1998-02-24 A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof SE9800550D0 (sv)

Priority Applications (18)

Application Number Priority Date Filing Date Title
SE9800550A SE9800550D0 (sv) 1998-02-24 1998-02-24 A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
MXPA00008172A MXPA00008172A (es) 1998-02-24 1999-02-24 Preparacion farmacologica que comprende un agonista del receptor tipo 2 de la angiotensina ii y utilizacion de la misma.
JP2000533135A JP2002504516A (ja) 1998-02-24 1999-02-24 アンギオテンシンｉｉ型２リセプタ作用薬を含む医薬製剤およびその使用
CN99803230A CN1291104A (zh) 1998-02-24 1999-02-24 含有血管紧张素ⅱ2型受体激动剂的药物制剂及其应用
IDW20001909A ID26639A (id) 1998-02-24 1999-02-24 Sediaan farmasi yang mengandung agonis reseptor angiotensin ii jenis 2 dan pemakaiannya
IL13799099A IL137990A0 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof
PCT/SE1999/000262 WO1999043339A1 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof
EEP200000481A EE200000481A (et) 1998-02-24 1999-02-24 Angiotensiin II 2. tüüpi retseptori agonisti sisaldav farmatseutiline preparaat ja selle kasutamine
AU27537/99A AU755949B2 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
CA002319123A CA2319123A1 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof
KR1020007009295A KR20010041211A (ko) 1998-02-24 1999-02-24 안지오텐신 ιι 타입 2 수용체 효능제를 포함하는 제약제제 및 그의 용도
BR9908188-1A BR9908188A (pt) 1998-02-24 1999-02-24 Preparação farmacêutica, uso de um agonista de receptor de tipo 2 de angiotensina ii ou de um seu sal fisiologicamente aceitável, e, processo para tratamento e/ou prevenção de uma afecção selecionada do grupo consistindo de distúrbios do trato alimentar, tais como dispepsia, sìndrome de intestino irritável e/ou insuficiência múltipla de órgãos em um paciente
NZ506188A NZ506188A (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
HU0101411A HUP0101411A3 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof
SK1152-2000A SK11522000A3 (sk) 1998-02-24 1999-02-24 Farmaceutický prípravok obsahujúci agonistu receptora angiotenzínu ii typu 2 a jeho použitie
EP99908017A EP1066048A1 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof
IS5594A IS5594A (is) 1998-02-24 2000-08-21 Lyfjablanda sem inniheldur gerandefni angíótensínII viðtaka af gerð 2 og notkun hennar
NO20004215A NO20004215L (no) 1998-02-24 2000-08-23 Et farmasøytisk preparat som omfatter en angiotensin II type 2-reseptoragonist, og anvendelse derav

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9800550A SE9800550D0 (sv) 1998-02-24 1998-02-24 A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof

Publications (1)

Publication Number Publication Date
SE9800550D0 true SE9800550D0 (sv) 1998-02-24

Family

ID=20410283

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9800550A SE9800550D0 (sv) 1998-02-24 1998-02-24 A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof

Country Status (18)

Country Link
EP (1) EP1066048A1 (is)
JP (1) JP2002504516A (is)
KR (1) KR20010041211A (is)
CN (1) CN1291104A (is)
AU (1) AU755949B2 (is)
BR (1) BR9908188A (is)
CA (1) CA2319123A1 (is)
EE (1) EE200000481A (is)
HU (1) HUP0101411A3 (is)
ID (1) ID26639A (is)
IL (1) IL137990A0 (is)
IS (1) IS5594A (is)
MX (1) MXPA00008172A (is)
NO (1) NO20004215L (is)
NZ (1) NZ506188A (is)
SE (1) SE9800550D0 (is)
SK (1) SK11522000A3 (is)
WO (1) WO1999043339A1 (is)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821953B1 (en) 1999-12-16 2004-11-23 University Of Southern California Methods for treating and preventing damage to mucosal tissue
WO2001043761A2 (en) * 1999-12-16 2001-06-21 University Of Southern California Methods for treating and preventing damage to mucosal tissue
DE60222409T2 (de) 2001-05-31 2008-09-25 Vicore Pharma Ab Trizyklische verbindungen, nützlich als angiotensin ii agonisten
CA2604797C (en) 2005-04-12 2013-05-28 Vicore Pharma Ab New tricyclic angiotensin ii agonists
MX2007012633A (es) 2005-04-12 2008-01-11 Vicore Pharma Ab Nuevos agonistas biciclicos de angiotensina ii.
KR101284573B1 (ko) 2005-04-12 2013-07-11 바이코어 파마 아베 신규한 트리시클릭 안지오텐신 ⅱ 아고니스트
KR101423898B1 (ko) * 2005-12-14 2014-07-28 암브룩스, 인코포레이티드 비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
US8835471B2 (en) 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
EP2455388A1 (en) 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
US20150119329A1 (en) * 2012-04-16 2015-04-30 New York University Modulation of angiotensin ii receptors for the prevention and treatment of malaria cerebral
AU2016227486A1 (en) 2015-03-02 2017-08-17 Vicore Pharma Ab Angiotensin ll receptor agonist for treating pulmonary fibrosis
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
GB201818164D0 (en) 2018-11-07 2018-12-19 Vicore Pharma Ab New composition
WO2021023698A1 (en) 2019-08-02 2021-02-11 Lanthiopep B.V Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
GB201913603D0 (en) 2019-09-20 2019-11-06 Vicore Pharma Ab New compounds
PH12022552413A1 (en) 2020-03-19 2024-01-08 Vicore Pharma Ab Novel compounds useful in the treatment and/or prevention of a disease, disorder or condition associated with angiotensin ii
GB202004094D0 (en) 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
GB202006074D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006081D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006079D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202013721D0 (en) 2020-09-01 2020-10-14 Vicore Pharma Ab New compounds
EP4313953A1 (en) 2021-03-23 2024-02-07 Vicore Pharma AB Selective angiotensin ii receptor ligands
GB202104038D0 (en) 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
GB202104033D0 (en) 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
CA3222721A1 (en) 2021-07-09 2023-01-12 Nadia Nasser PETERSEN New selective angiotensin ii compounds
GB202115303D0 (en) 2021-10-25 2021-12-08 Vicore Pharma Ab New formulation
GB202201723D0 (en) 2022-02-10 2022-03-30 Vicore Pharma Ab New use
CA3249539A1 (en) 2022-02-10 2023-08-17 Vicore Pharma Ab USE OF BULOXIBUTID FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
KR20250002355A (ko) 2022-04-06 2025-01-07 우한 휴먼웰 이노베이티브 드러그 리서치 앤드 디벨롭먼트 센터 리미티드 컴퍼니 Ａｔ２ｒ 작용제
GB2640807A (en) 2022-12-22 2025-11-05 Vicore Pharma Ab A method of treating a patient diagnosed with an interstitial lung disease
CN120569378A (zh) 2023-01-09 2025-08-29 维科尔药物公司 选择性血管紧张素ii化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444067A (en) * 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
WO1996014060A1 (en) * 1994-11-04 1996-05-17 Marklund Stefan L Use of receptor agonists to stimulate superoxide dismutase activity
SE9501881D0 (sv) * 1995-05-19 1995-05-19 Astra Ab New pharmacological use of AII-receptor antagonists
US5834432A (en) * 1995-06-06 1998-11-10 The University Of Southern California Use of angiotensin II Type 2 receptor agonists in tissue repair
SE9502219D0 (sv) * 1995-06-19 1995-06-19 Astra Ab Novel medical use

Also Published As

Publication number Publication date
AU2753799A (en) 1999-09-15
CN1291104A (zh) 2001-04-11
HUP0101411A3 (en) 2002-11-28
EE200000481A (et) 2002-02-15
WO1999043339A1 (en) 1999-09-02
IL137990A0 (en) 2001-10-31
SK11522000A3 (sk) 2001-04-09
MXPA00008172A (es) 2002-06-21
NZ506188A (en) 2003-04-29
BR9908188A (pt) 2000-10-24
ID26639A (id) 2001-01-25
CA2319123A1 (en) 1999-09-02
NO20004215D0 (no) 2000-08-23
KR20010041211A (ko) 2001-05-15
JP2002504516A (ja) 2002-02-12
EP1066048A1 (en) 2001-01-10
AU755949B2 (en) 2003-01-02
IS5594A (is) 2000-08-21
HUP0101411A2 (hu) 2002-03-28
NO20004215L (no) 2000-09-18

Similar Documents

Publication Publication Date Title
BR9908188A (pt) Preparação farmacêutica, uso de um agonista de receptor de tipo 2 de angiotensina ii ou de um seu sal fisiologicamente aceitável, e, processo para tratamento e/ou prevenção de uma afecção selecionada do grupo consistindo de distúrbios do trato alimentar, tais como dispepsia, sìndrome de intestino irritável e/ou insuficiência múltipla de órgãos em um paciente
Rabinowitz et al. The effect of clozapine on saliva flow rate: a pilot study
EA200501496A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
DE69727922D1 (de) Schnell zerfallende orale dosierungsform
DE69132688D1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
CA2321700A1 (en) Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
BG101118A (en) Therapeutical compounds
BR9908030A (pt) Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado
CA2338005A1 (en) Peptide antagonists of zonulin and methods for use of the same
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
PT758241E (pt) Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses
Baird et al. Non-antibiotic anti-diarrhoeal drugs: Factors affecting oral bioavailability of berberine and loperamide in intestinal tissue
NZ516477A (en) Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
JP2004537500A5 (is)
RU2218917C2 (ru) Применение специфического антагониста 5ht2 рецепторов для приготовления лекарств, пригодных для лечения синдрома апноэ во сне
Bharucha et al. Taking a lesson from microbial diarrheagenesis in the management of chronic constipation
CA2120062A1 (en) Use of Sulodexide and of Medicines Containing It in the Treatment of Diabetic Nephropathy
SE9502219D0 (sv) Novel medical use
BRPI0412430A (pt) polipeptìdeo agonista do receptor de zot e zonulina
JP2002519391A5 (is)
KR970701724A (ko) 스타니어스 단백질인 스타니오칼신의 소체(Corpuscles of stannius protein, stanniocalcin)
BR0107960A (pt) Tratamento de condições alérgicas e inflamatórias
CA2433785A1 (en) Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
Stancic-Rokotov et al. Ethanol gastric lesion aggravated by lung injury in rat. Therapy effect of antiulcer agents